About Ariad Pharmaceuticals
Ariad Pharmaceuticals is a Healthcare company based in Cambridge (United States) founded in 1991, and was acquired by Takeda in January 2017. Targeted small molecules to treat variety of cancer such as chronic myeloid leukemia, acute lymphoblastic leukemia, lung and biliary. Ariad Pharmaceuticals has raised $46 million across 7 funding rounds from investors including Credit Suisse and Takeda Pharmaceuticals. The company has 328 employees. Its focus areas include Life Sciences, Oncology, Drugs and Blood Cancer. Its competitors include Adicet Bio, Orca Bio and Ossium Health; 3 of its 3 listed competitors have raised funding.
Company details
Ariad Pharmaceuticals is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. Its product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), A32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL). Also investigating Iclusig for the treatment of other cancer such as lung, biliary. Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK) to treat non-small cell lung cancer (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR) and it is developing it to treat non-small cell lung cancer.
- Annual Revenue$118.8 M (USD)13as on Dec 31, 2015
- Net Profit-$231.16 M (USD)-42as on Dec 31, 2015
- EBITDA-$217.28 M (USD)-36as on Dec 31, 2015
- Total Equity Funding$46M (USD)
in 7 rounds
- Latest Funding Round$200M (USD), Post-IPO
Jun 2014
- InvestorsCredit Suisse
& 1 more
- Employee Count328
- Acquired byTakeda
(Jan 2017)
Funding Insights of Ariad Pharmaceuticals
Ariad Pharmaceuticals has successfully raised a total of $46M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46M
- Total Rounds 7
- Last Round Post-IPO — $200M
- First Round $46M
(Mar 1992)
- Investors Count 1
All 7 funding rounds of Ariad Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2014 | $200M | Post-IPO | – | – | – |
| Oct 2006 | $14.5M | Post-IPO | – | – | |
| Jan 2002 | $7.6M | Post-IPO | – | – | – |
| Jan 1999 | $5.75M | Post-IPO | – | – | – |
| May 1998 | $9.3M | Post-IPO | – | – | – |
| Jun 1997 | $2.4M | Post-IPO | – | – | – |
| Mar 1992 | $46M | Private Equity Round | – | – | – |
2 investors in total: 2 institutional.
Investors in Ariad Pharmaceuticals
Ariad Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Credit Suisse and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Wealth management, asset management, and investment banking services are offered. | 1856 | credit-suisse.com | Zurich, Switzerland | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for Ariad Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ariad Pharmaceuticals
5 dated milestones of Ariad Pharmaceuticals across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Ariad Pharmaceuticals is founded.
- Funding First funding round of $46.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $200.0M.
- Exit Acquired by Takeda.
Competitors of Ariad Pharmaceuticals
Ariad Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Adicet Bio, Orca Bio and Ossium Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adicetbio.com | 2014 | Menlo Park, United States | $51M | 86 | Immune cell therapies for cancer treatment are developed. | |
| orcabio.com | 2016 | Menlo Park, United States | $300M | 66 | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | |
| ossiumhealth.com | 2016 | San Francisco, United States | $125.41M | Ossium Health is focused on bioengineering for improved health. |
Detailed competitors of Ariad Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ariad Pharmaceuticals
Websites that share an audience with Ariad Pharmaceuticals (ariad.com).
Websites whose visitors overlap most with Ariad Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vrtx.com | 100% | 342.2K | #151,023 | View details | |
| arqule.com | 96% | View details | |||
| halozyme.com | 82% | 11.6K | #1,481,510 | View details | |
| endo.com | 82% | 10K | #2,323,439 | View details | |
| theravance.com | 82% | 4.4K | #4,418,406 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for Ariad Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Ariad Pharmaceuticals (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ariad Pharmaceuticals
Complete news archive for Ariad Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ariad Pharmaceuticals
Ariad Pharmaceuticals was founded in 1991 and raised its 1st funding round 1 year after it was founded.
Ariad Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Ariad Pharmaceuticals is a funded company, having raised a total of $46M across 7 funding rounds to date. The company's 1st funding round was a Private Equity Round of $46M, raised on Mar 1992.
Ariad Pharmaceuticals has 328 employees.
Annual revenue of Ariad Pharmaceuticals is $118.8M as on Dec 31, 2015.
Ariad Pharmaceuticals is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. Its product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), A32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL). Also investigating Iclusig for the treatment of other cancer such as lung, biliary. Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK) to treat non-small cell lung cancer (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR) and it is developing it to treat non-small cell lung cancer.
Ariad Pharmaceuticals's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Ariad Pharmaceuticals has 2 investors. Key investors include Credit Suisse, and Takeda Pharmaceuticals.
Yes. Ariad Pharmaceuticals was acquired by Takeda in January 2017.